# Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma

> **NCT00569309** · NA · COMPLETED · sponsor: **Ohio State University Comprehensive Cancer Center** · enrollment: 30 (actual)

## Conditions studied

- Lymphoma
- Multiple Myeloma and Plasma Cell Neoplasm
- Small Intestine Cancer

## Interventions

- **BIOLOGICAL:** Streptococcus pneumoniae
- **OTHER:** laboratory correlative studies
- **OTHER:** quality-of-life assessment

## Key facts

- **NCT ID:** NCT00569309
- **Lead sponsor:** Ohio State University Comprehensive Cancer Center
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2007-12-12
- **Primary completion:** 2011-07-29
- **Final completion:** 2011-07-29
- **Target enrollment:** 30 (ACTUAL)
- **Last updated:** 2018-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00569309

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00569309, "Immune Reconstitution After Autologous Hematopoietic Stem Cell Transpl for High-Risk Lymphoma". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT00569309. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*